中华胃肠外科杂志
中華胃腸外科雜誌
중화위장외과잡지
CHINESE JOURNAL OF GASTROINTESTINAL SURGERY
2010年
9期
661-663
,共3页
黄常新%李朝阳%姜贻乾%段广亮%王青青
黃常新%李朝暘%薑貽乾%段廣亮%王青青
황상신%리조양%강이건%단엄량%왕청청
结直肠肿瘤%化学疗法%T淋巴细胞,调节性%细胞因子
結直腸腫瘤%化學療法%T淋巴細胞,調節性%細胞因子
결직장종류%화학요법%T림파세포,조절성%세포인자
Colorectal neoplasms%Chemotherapy%T lymphocytes,regulatory%Cytokines
目的 研究FOLFOX方案化疗对晚期结直肠癌患者免疫功能的影响.方法 43例晚期结直肠癌患者中22例接受了FOLFOX方案化疗(化疗组),21例未接受化疗(对照组).分别于化疗前、化疗结束时和化疗结束3个月后,取患者外周静脉血,采用抗体标记流式细胞仪检测外周血CD4+T细胞中CD4+CD25+Foxp3+T细胞所占比例;并通过ELISA法检测外周血中Th1/Th2细胞因子(IL-2、IFN-γ、IL-4和IL-10)水平.结果 化疗结束时,相对于化疗前和对照组,化疗组CD4+CD25+Foxp3+T细胞比例显著降低 [(4.15±0.56)%比(5.60±0.88)%和(5.38±0.92)%,均P＜0.01];外周血IL-4和IL-10水平亦显著降低,IFN-γ和IL-2水平则明显升高(均P＜0.01).化疗结束后3个月,CD4+CD25+Foxp3+T细胞比例略微升高 [(4.53±0.58)%],但仍低于化疗前和对照组(P＜0.01);而IFN-γ、IL-2、IL-4和IL-10则恢复到化疗前和对照组同期水平(均P＜0.01).结论 FOLFOX化疗可降低晚期结直肠癌患者的调节性T细胞的比例,引起Th1/Th2细胞因子平衡向Th1漂移,从而有利于患者肿瘤免疫抑制的解除.
目的 研究FOLFOX方案化療對晚期結直腸癌患者免疫功能的影響.方法 43例晚期結直腸癌患者中22例接受瞭FOLFOX方案化療(化療組),21例未接受化療(對照組).分彆于化療前、化療結束時和化療結束3箇月後,取患者外週靜脈血,採用抗體標記流式細胞儀檢測外週血CD4+T細胞中CD4+CD25+Foxp3+T細胞所佔比例;併通過ELISA法檢測外週血中Th1/Th2細胞因子(IL-2、IFN-γ、IL-4和IL-10)水平.結果 化療結束時,相對于化療前和對照組,化療組CD4+CD25+Foxp3+T細胞比例顯著降低 [(4.15±0.56)%比(5.60±0.88)%和(5.38±0.92)%,均P＜0.01];外週血IL-4和IL-10水平亦顯著降低,IFN-γ和IL-2水平則明顯升高(均P＜0.01).化療結束後3箇月,CD4+CD25+Foxp3+T細胞比例略微升高 [(4.53±0.58)%],但仍低于化療前和對照組(P＜0.01);而IFN-γ、IL-2、IL-4和IL-10則恢複到化療前和對照組同期水平(均P＜0.01).結論 FOLFOX化療可降低晚期結直腸癌患者的調節性T細胞的比例,引起Th1/Th2細胞因子平衡嚮Th1漂移,從而有利于患者腫瘤免疫抑製的解除.
목적 연구FOLFOX방안화료대만기결직장암환자면역공능적영향.방법 43례만기결직장암환자중22례접수료FOLFOX방안화료(화료조),21례미접수화료(대조조).분별우화료전、화료결속시화화료결속3개월후,취환자외주정맥혈,채용항체표기류식세포의검측외주혈CD4+T세포중CD4+CD25+Foxp3+T세포소점비례;병통과ELISA법검측외주혈중Th1/Th2세포인자(IL-2、IFN-γ、IL-4화IL-10)수평.결과 화료결속시,상대우화료전화대조조,화료조CD4+CD25+Foxp3+T세포비례현저강저 [(4.15±0.56)%비(5.60±0.88)%화(5.38±0.92)%,균P＜0.01];외주혈IL-4화IL-10수평역현저강저,IFN-γ화IL-2수평칙명현승고(균P＜0.01).화료결속후3개월,CD4+CD25+Foxp3+T세포비례략미승고 [(4.53±0.58)%],단잉저우화료전화대조조(P＜0.01);이IFN-γ、IL-2、IL-4화IL-10칙회복도화료전화대조조동기수평(균P＜0.01).결론 FOLFOX화료가강저만기결직장암환자적조절성T세포적비례,인기Th1/Th2세포인자평형향Th1표이,종이유리우환자종류면역억제적해제.
Objective To examine the influence of chemotherapy with FOLFOX protocol(CT-F) on the immunologic function in patients with advanced colorectal cancer. Methods A total of 43 patients with advanced colorectal cancer were included. Patients who received FOLFOX chemotherapy (Group A,n＝22) were compared to those who did not(Group B,n＝21). Blood was obtained from peripheral vein before chemotherapy(T0), at the time of completion of chemotherapy(T1), and 3 months after completion of chemotherapy(T2) to detect the percentage of regulatory T lymphocytes(CD4+CD25+ Foxp3+T cells) in total T lymphocytes using fluorescence activated cell sorter(FACS). The level of Th1/Th2 cytokines in the serum including interleukin-2(IL-2), interleukin-4(IL-4), interleukin-10(IL-10) and interferon-γ (IFN-γ) were detected by enzyme-linked immunoabsorbent assay(ELISA). Results The percentage of regulative T lymphocyte was significantly lower at T1, which increased after chemotherapy but was still lower than that at T0 and that in Group B [(4.15±0.56)%, (5.60±0.88)%, and(5.38±0.92)%, all P＜0.01]. The levels of IL-4, IL-10 decreased at T1, and increased to the normal level at T2 compared with those at T0 or those in the control group (all P＜0.01). In contrast, the levels of IL-2 and IFN-γ increased significantly at T1 and decreased to the normal level at T2 during the entire observation period. Conclusion For patients with advanced colorectal cancer, FOLFOX chemotherapy can decrease the proportion of regulatory T lymphocytes and results in Th1/Th2 cytokine drift to Th1 type. Therefore, FOLFOX may help the release from the anticancer immune inhibition.
